Integra LifeSciencesIART
IART
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
3,790% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $345K
26% more capital invested
Capital invested by funds: $1.24B [Q3] → $1.57B (+$327M) [Q4]
12% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 69
0% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 40
0.94% less ownership
Funds ownership: 90.74% [Q3] → 89.8% (-0.94%) [Q4]
2% less funds holding
Funds holding: 222 [Q3] → 218 (-4) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$35
62%
upside
Avg. target
$35
62%
upside
High target
$35
62%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Citizens Capital Markets David Turkaly 31% 1-year accuracy 8 / 26 met price target | 62%upside $35 | Market Outperform Reiterated | 26 Feb 2025 |
Financial journalist opinion
Based on 5 articles about IART published over the past 30 days
Neutral
Zacks Investment Research
6 days ago
Is This the Right Time to Hold Integra Stock in Your Portfolio?
IART stays on investors' radar courtesy of its strong prospects in the CSS segment and international growth.

Neutral
GlobeNewsWire
1 week ago
Notice to Long-Term Integra Lifesciences Holdings Corporation (NASDAQ: IART) Shareholders: Grabar Law Investigates Claims on Your Behalf
PHILADELPHIA, March 22, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company.

Neutral
GlobeNewsWire
2 weeks ago
Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET.

Neutral
Seeking Alpha
3 weeks ago
Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade)
Integra LifeSciences had a rough 2024 as the company's quality control remediation efforts had a bigger than expected negative impact on results. Q4 '24 offered some stability with organic revenue growth and improved adjusted gross margins. 2025 guidance looks cautious, and a big cut to Q1 '25 expectations suggests that management may be pulling forward some of the lingering remediation costs.

Positive
Zacks Investment Research
4 weeks ago
Integra Q4 Earnings Beat Estimates, Revenues Rise Y/Y, Stock Up
IART delivers better-than-expected earnings in the fourth quarter of 2024.

Neutral
GlobeNewsWire
1 month ago
INTEGRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQ: IART) on behalf of long-term stockholders following a class action complaint that was filed against Integra on September 12, 2023 with a Class Period from March 11, 2019 to May 22, 2023. Our investigation concerns whether the board of directors of Integra have breached their fiduciary duties to the company.

Neutral
Seeking Alpha
1 month ago
Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q4 2024 Earnings Call Transcript

Positive
Zacks Investment Research
1 month ago
Integra (IART) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Positive
Zacks Investment Research
1 month ago
Integra LifeSciences (IART) Surpasses Q4 Earnings Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.89 per share a year ago.

Neutral
GlobeNewsWire
1 month ago
Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance
PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2024.

Charts implemented using Lightweight Charts™